L-S,R-buthionine sulfoximine: Historical development and clinical issues

Chemico-Biological Interactions

Volumn 111-112, Issue , 1998, Pages 239-254

  Bailey, Howard H ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Glutathione; L S,R buthionine sulfoximine; Tumor

Indexed keywords

BUTHIONINE SULFOXIMINE; GLUTATHIONE; MELPHALAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CANCER; CANCER RESISTANCE; CLINICAL TRIAL; CYTOTOXICITY; GLUTATHIONE METABOLISM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTE; NONHUMAN; PHASE 1 CLINICAL TRIAL;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUTHIONINE SULFOXIMINE; DRUG RESISTANCE; ENZYME INHIBITORS; FEMALE; GLUTAMATE-CYSTEINE LIGASE; HISTORY, 20TH CENTURY; HUMANS; MALE; MELPHALAN; NEOPLASMS;

EID: 4243987802     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-2797(97)00164-6     Document Type: Article

References (39)

1. Meister A., Anderson M.E. Glutathione. Annu. Rev. Biochem. 52:1983;711-760.
2. Richman P.G., Meister A. Regulation of γ-glutamylcysteine synthetase by nonallosteric feedback inhibition of glutathione. J. Biol. Chem. 250:1975;1422-1426.
3. Ball C.R., Connors T.A., Double J.A., Ujhazy V., Whisson M.E. Comparison of nitrogen mustard-sensitive and -resistant Yoshida sarcomas. Int. J. Cancer. 1:1966;319-327.
4. Suzukake K., Petro B.J., Vistica D.T. Reduction in glutathione content of L-PAM resistant L1210 cells confers drug sensitivity. Biochem. Pharmacol. 31:1982;121-124.
5. Green J.A., Vistica D.T., Young R.C., Hamilton T.C., Rogan A.M., Ozols R.F. Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion. Cancer Res. 44:1984;5427-5431.
6. Suzukake K., Vistica B.P., Vistica D.T. Dechlorination of L-phenylalanine mustary by sensitive and resistant tumor cells and its relationship to intracellular glutathione content. Biochem. Pharmacol. 32:1983;165-167.
7. Begleiter A., Grover J., Froese E., Goldenberg G.J. Membrane transport, sulfhydryl levels and DNA cross-linking in Chinese hamster ovary cell mutants sensitive and resistant to melphalan. Biochem. Pharmacol. 32:1983;293-300.
8. Kramer R.A., Zakher J., Kim G. Role of the glutathione redox cycle in acquired and de novo multidrug resistance. Science. 241:1988;694-697.
9. Griffith O.W., Meister A. Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine). J. Biol. Chem. 254:1979;7558-7560.
10. Andrews P.A., Murphy M.P., Howell S.B. Differential potentiation of alkylating an platinating agent cytotoxicity in human ovarian carcinoma cells by glutathione depletion. Cancer Res. 45:1985;6250-6253.
11. Kramer R.A., Greene D., Ahmad S., Vistica D.T. Chemosensitization of L-phenylalanine mustard by the thiol-modulating agent buthionine sulfoximine. Cancer Res. 47:1987;1593-1597.
12. Somfai-Relle S., Suzukake K., Vistica B.P., Vistica D.T. Reduction in cellular glutathione by buthionine sulfoximine and sensitization of murine tumor cells resistant to L-phenylalanine mustard. Biochem. Pharmacol. 33:1984;485-490.
13. Ozols R.F., Louie K.G., Plowman J., Behrens B.C., Fine R.L., Dykes D., Hamilton T.C. Enhanced melphalan cytotoxicity in human ovarian cancer in vitro and in tumor-bearing nude mice by buthionine sulfoximine depletion of glutathione. Biochem. Pharmacol. 36:1987;147-153.
14. Bailey H.H., Gipp J.J., Ripple M., Wilding G., Mulcahy R.T. Increase in γ-glutamylcysteine synthetase activity and steady-state messenger RNA levels in melphalan-resistant DU-145 human prostate carcinoma cells expressing elevated glutathione level. Cancer Res. 52:1992;5115-5118.
15. Godwin A.K., Meister A., O'Dwyer P.J., Huang C.S., Hamilton T.C., Anderson M.E. High resistance to cisplatinum in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc. Natl. Acad. Sci. USA. 89:1992;3070-3074.
16. Mulcahy R.T., Bailey H.H., Gipp J.J. Transfection of complementary DNAs for the heavy and light subunits of human γ-glutamylcysteine synthetase results in an elevation of intracellular glutathione and resistance to melphalan. Cancer Res. 55:1995;4771-4775.
17. Arrick B.A., Nathan C.F. Glutathione metabolism as a determinant of therapeutic efficacy: A review. Cancer Res. 44:1984;4224-4232.
18. Shrieve D.C., Li G.C., Astromoff A., Harris J.W. Cellular glutathione, thermal sensitivity, and thermotolerance in Chinese hamster fibroblasts and their heat-resistant variants. Cancer Res. 46:1986;1684-1687.
19. Dusre L., Mimnaugh E.G., Myers C.E., Sinha B.K. Potentiation of doxorubicin cytotoxicity by buthionine sulfoximine in multidrug-resistant human breast tumor cells. Cancer Res. 49:1989;511-515.
20. Zaman G.J.R., Lankelma J., van Tellingen O., Beijnen J., Dekker H., Paulusma C., Oude Elferink R.P.J., Baas F., Borst P. Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein. Proc. Natl. Acad. Sci. USA. 92:1995;7690-7694.
21. Vanhoefer U., Cao S., Minderman H., Toth K., Skenderis B.S., Slovak M.L., Rustum Y.M. D,L-Buthionine-(S,R)-sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors. Clin. Cancer Res. 2:1996;1961-1968.
22. Tew K.D. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res. 54:1994;4313-4320.
23. Ali-Osman F. Quenching of DNA cross-link precursors of chloroethyl-nitrosoureas and attenuation of DNA interstrand cross-linking by glutathione. Cancer Res. 49:1989;5258-5261.
24. Alaouni-Jamali M.A., Panasci L., Centurioni G.M., Schecter R., Lehnert S., Batist G. Nitrogen mustard-DNA interaction in melphalan-resistant mammary carcinoma cells with elevated intracellular glutathione and glutathione-S-transferase. Cancer Chemother. Pharmacol. 30:1992;341-347.
25. Griffith O.W. Mechanism of action, metabolism, and toxicity of buthionine sulfoximine and its higher homologs, potent inhibitors of glutathione synthesis. J. Biol. Chem. 257:1982;13704-13712.
26. Hansson J., Edgren M., Ehrsson H., Ringborg U., Nilsson B. Effect of D,L-buthionine-S,R-sulfoximine on cytotoxicity and DNA cross-linking induced by bifunctional DNA-reactive cytostatic drugs in human melanoma cells. Cancer Res. 48:1988;19-26.
27. Kable E.P.W., Favier D., Parsons P.G. Sensitivity of human melanoma cells to L-dopa and D,L-buthionine-(S,R)-sulfoximine. Cancer Res. 49:1989;2327-2331.
28. Prezioso J.A., Fitzgerald G.B., Wick M.M. Melanoma cytotoxicity of buthionine sulfoximine (BSO) alone and in combination with 3,4-dihydroxybenzylamine and melphalan. J. Invest. Dermatol. 99:1992;289-293.
29. Anderson C.P., Tsai J.M., Chan W.W., Liu R.M., Forman H.J., Reynolds C.P. Buthionine sulfoximine (BSO) is cytotoxic via apoptosis and synergistically enhances the activity of melphalan (L-PAM) in human neuroblastoma cell lines. Eur. J. Cancer. 33:1997;2016-2019.
30. Lee F.Y.F., Allalunis-Turner M.J.A., Siemann D.W. Depletion of tumour versus normal tissue glutathione by buthionine sulfoximine. Br. J. Cancer. 56:1987;33-38.
31. Skapek S.X., Colvin O.M., Griffith O.W., Groothuis D.R., Colapinto E.V., Lee Y., Hilton J., Elion G.B., Bigner D.D., Friedman H.S. Buthionine sulfoximine-mediated depletion of glutathione in intracranial human glioma-derived xenografts. Biochem. Pharmacol. 37:1988;4313-4317.
32. Vistica D.T., Ahmad S. Acquired resistance of tumor cells to L-phenylalanine mustard: Implications for the design of a clinical trial involving glutathione depletion. Taniguchi N., Higashi T., Sakamoto Y., Meister A. Glutathione Centennial: Molecular Perspectives and Clinical Implications. 1989;300-315 Academic Press, New York.
33. Bailey H.H., Mulcahy R.T., Tutsch K.D., Arzoomanian R.Z., Alberti D., Tombes M.B., Wilding G., Pomplun M., Spriggs D.R. Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: An attempt at modulation of glutathione. J. Clin. Oncol. 12:1994;194-205.
34. O'Dwyer P.J., Hamilton T.C., LaCreta F.P., Gallo J.M., Kilpatrick D., Halbherr T., Brennan J., Bookman M.A., Hoffman J., Young R.C., Comis R.L., Ozols R.F. Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer. J. Clin. Oncol. 14:1996;249-256.
35. Bailey H.H., Ripple G., Tutsch K.D., Arzoomanian R.Z., Alberti D., Feierabend C., Mahvi D., Schink J., Pomplun M., Mulcahy R.T., Wilding G. Phase I study of continuous-infusion L-S,R-buthionine sulfoximine with intravenous melphalan. J. Natl. Cancer Inst. 89:1997;1789-1796.
36. Allalunis-Turner M.J., Lee F.Y.F., Siemann D.W. Comparison of glutathione levels in rodent and human tumor cells grown in vitro and in vivo. Cancer Res. 48:1988;3657-3660.
37. Cook J.A., Pass H.I., Iype S.N. Cellular glutathione and thiol measurements from surgically resected human lung tumor and normal lung tissue. Cancer Res. 51:1991;4287-4294.
38. Berger S.J., Gosky D., Zborowska E., Willson J.K.V., Berger N.A. Sensitive enzymatic cycling assay for glutathione: Measurements of glutathione content and its modulation by buthionine sulfoximine in vivo and in vitro in human colon cancer. Cancer Res. 54:1994;4077-4083.
39. Malaker K., Hurwitz S.J., Bump E.A., Griffith O.W., Lai L.L., Riese N., Coleman C.N. Pharmacodynamics of prolonged treatment with L,S-buthionine sulfoximine. Int. J. Radiat. Oncol. Biol. Phys. 29:1994;407-412.